Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update

doi:10.19982/j.issn.1000-6621.20240191

Chinese Journal of Antituberculosis ›› 2024, Vol. 46 ›› Issue (8): 874-876.doi: 10.19982/j.issn.1000-6621.20240191

• Interpretation of Standards • Previous Articles Next Articles

Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update

Yang Liangzi, Zhang Peize, Lu Shuihua()

Shenzhen Third People’s Hospital/The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology/National Clinical Research Center for Infectious Disease, Shenzhen 518112, China

Received:2024-05-15 Online:2024-08-10 Published:2024-08-01
Contact: Lu Shuihua E-mail:lushuihua66@126.com
Supported by:
Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties(结核病科);Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties(SZGSP010);Shenzhen Clinical Research Center for Tuberculosis(20210617141509001);Guangdong Clinical Research Center for Tuberculosis(2020B1111170014)

Abstract

Abstract:

On April 9, 2024, the World Health Organization published the updated guidelines for the Co-administration of Treatments for Drug-resistant Tuberculosis and Hepatitis C, as part of a rapid communication effort. This paper elucidates key aspects of the guideline, detailing the epidemiological background, pivotal evidence underpinning the updates, and significant findings. A comprehensive summary and forthcoming steps for the guideline’s advancement are presented. Additionally, the authors evaluate the practical applicability of these guidelines in Chinese clinical settings and propose areas for future research, aiming to enhance the management of these coexisting conditions.

Key words: Tuberculosis, pulmonary, Drug resistance, bacterial, Hepatitis C, Comorbidity, Disease management

CLC Number:

R52
R512.6

Yang Liangzi, Zhang Peize, Lu Shuihua. Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update[J]. Chinese Journal of Antituberculosis, 2024, 46(8): 874-876. doi: 10.19982/j.issn.1000-6621.20240191

References 7

[1]	World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization, 2023.
[2]	Olaru ID, Beliz Meier M, Mirzayev F, et al. Global prevalence of hepatitis B or hepatitis C infection among patients with tuberculosis disease: systematic review and meta-analysis. EClinicalMedicine, 2023, 58:101938. doi:10.1016/j.eclinm.2023.101938.
[3]	Merza MA, Haji SM, Alsharafani AM, et al. Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan: Are HBsAg and anti-HCV prerequisite screening parameters in tuberculosis control program?. Int J Mycobacteriol, 2016, 5(3):313-317. doi:10.1016/j.ijmyco.2016.06.019. pmid: 27847016
[4]	World Health Organization. Co-administration of treatment for drug-resistant tuberculosis and hepatitis C: rapid communication. Geneva: World Health Organization, 2024.
[5]	Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol, 2022, 7(5): 396-415. doi:10.1016/S2468-1253(21)00472-6.
[6]	中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2022年版). 中华肝脏病杂志, 2022, 30(12): 1332-1348. doi:10.3760/cma.j.cn501113-20221220-00605.
[7]	国家卫生健康委办公厅,科技部办公厅,工业和信息化部办公厅, 等. 关于印发消除丙型肝炎公共卫生危害行动工作方案(2021—2030年)的通知. 国卫办疾控函〔2021〕492号. 2021-08-31.

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397.
[2]	Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431.
[3]	Zhang Guoqin, Qu Ting, Meng Qinglin, Zhou Lin, Liu Eryong. Implementation update of strategy for the control of tuberculosis and HIV/AIDS co-infection in China [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 12-17.
[4]	Cai Qinghe, Fu Hui, Chen Ruiming, Fan Youming, Yang Qingwei. Analysis of the clinical characteristics and influencing factors of pulmonary tuberculosis patients with diabetes mellitus in Shantou City from 2016 to 2022 [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 926-934.
[5]	Chai Dongyu, Qin Shuyi, Zhang Ronghua, Zou Nannan, Wang Xin. Analysis of risk factors for viral pneumonia combined with invasive pulmonary mycosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 750-755.
[6]	Fu Keyan, Zhu Bangzheng, Ye Jian. Research progress on interstitial lung disease combined with Mycobacterium tuberculosis infection [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 823-829.
[7]	Liu Guizhen, Deng Guofang. Interpretation of Evidence and research gaps identified during development of policy guidelines for tuberculosis (Second edition): tuberculosis related comorbidity [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 618-624.
[8]	Li Yao, Fang Zhe, Luo Danlin, Hu Yanmei, Tang Mi, Tang Zhigang, Wen Xinmin, Zhang Yong, Yao Bibo, Wang Qi, Yi Hengzhong. Clinical characteristics and prognosis of patients with novel coronavirus infection complicated with pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 687-698.
[9]	Yang Rui, Li Ling, Chen Jinou, Xu Lin. Analysis of influencing factors of anti-tuberculosis treatment effect for pulmonary tuberculosis patients complicated with diabetes in Yunnan Province from 2017 to 2021 [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 519-524.
[10]	Liu Meijun, Li Feng. Current situation and research progress of co-infection of HIV/AIDS and subclinical tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 596-600.
[11]	Wang Senlu, Liu Nianqiang, Wang Xinqi, Cao Mingqin, Wang Le, Wang Xijiang. Development and effectiveness of “Xinjiang Model” for tuberculosis prevention and control [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 141-144.
[12]	Bao Liangliang, Wang Xinqi, Zhang Yan, Cao Mingqin. Qualitative evaluation of the implementation status of tuberculosis prevention and control in Southern Xinjiang Uygur Autonomous Region: qualitative interviews based on grounded theories [J]. Chinese Journal of Antituberculosis, 2024, 46(2): 151-157.
[13]	Yang Jieying, Xiao Xincai, Du Yuhua, Lai Keng, He Liqian, Wang Ting, Lin Ying, He Weiyun. Analysis of epidemiological characteristics and therapeutic prognosis among pulmonary tuberculosis patients complicated with diabetes mellitus in Guangzhou City from 2014 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(12): 1504-1510.
[14]	Sun Qingfeng, Li Haoran, Pang Yu, Gao Mengqiu. Co-morbidity research progress of tuberculosis and depression [J]. Chinese Journal of Antituberculosis, 2024, 46(1): 106-111.
[15]	Liu Qiliang, Li Yuejie, Lei Mei. Clinicopathological features of 13 cases cervical lymph node tuberculosis complicated with metastatic carcinoma [J]. Chinese Journal of Antituberculosis, 2023, 45(9): 891-896.

Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 7

Related Articles 15

Recommended Articles

Metrics

Comments